The Claim
Among obese adults treated with tirzepatide or semaglutide, a higher proportion of female individuals achieve ≥15% weight loss compared to male individuals, with 74.9% of high responders being female for tirzepatide and 80.3% for semaglutide.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults using tirzepatide or semaglutide for weight loss, women make up a larger share of those who lose at least 15% of their body weight than men.
See the scientific wording
Among obese adults, women are more likely than men to achieve high weight loss (≥15%) with either tirzepatide or semaglutide, with 74.9% of high responders being female for tirzepatide and 80.3% for semaglutide, suggesting sex-based differences in treatment response.
Women have higher levels of hormones that make fat cells more responsive to weight-loss drugs, and their brains are more sensitive to signals that reduce hunger, leading to greater fat loss.
What the research says
1 studyStudy: Weight-loss dynamics with tirzepatide versus semaglutide
The study says more women than men lost a lot of weight on these drugs, but it doesn’t say exactly how many women made up the high-weight-loss group, so we can’t confirm the claim’s specific numbers.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.